Kit Combines Reverse Transcription and Quantitation Using the Droplet Digital™ PCR (ddPCR™) System
Hercules, CA — March 19, 2012 —The one-step RT-ddPCR kit for probes, introduced today by Bio-Rad Laboratories, Inc., provides researchers with the ability to measure target RNA molecules with precision and sensitivity for applications such as gene expression analysis, miRNA analysis, and viral load quantitation.
The one-step RT-ddPCR kit creates a new paradigm for the precise quantitation of RNA by combining reverse transcription with droplet digital PCR. Researchers can use the one-step RT-ddPCR kit for probes with Bio-Rad’s QX100™ Droplet Digital™ PCR system to determine small differences in copy number of target RNA that they were previously unable to measure using real-time PCR.
In combination with the QX100™ ddPCR™ system, the one-step RT-ddPCR kit for probes allows scientists to:
- Enrich for rare target RNA sequences
- Detect small differences in gene expression levels
- Determine copies of an RNA molecule without a standard curve
How It Works
The one-step RT-ddPCR kit for probes follows the ddPCR workflow except it partitions sample RNA instead of DNA or cDNA. The sample is partitioned into 20,000 droplets, with target and background RNA randomly distributed among them. After reverse transcription, the resulting cDNA is PCR amplified for target detection. Each droplet delivers a positive or negative fluorescent signal, indicating whether target RNA is present or absent. Positive and negative droplets are counted and software calculates the concentration of target RNA in copies per microliter.
For further details about the Droplet Digital PCR system, kits, and reagents, please visit http://bit.ly/ddPCR_QX100.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Richard Kurtz
Bio-Rad Laboratories, Inc.
510-741-5638
Richard_Kurtz@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 109
kli@chempetitive.com